Compare · DXCM vs PETV
DXCM vs PETV
Side-by-side comparison of DexCom Inc. (DXCM) and PetVivo Holdings Inc. (PETV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PETV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $28.08B, about 2265.9x PETV ($12.4M).
- DXCM has been more active in the news (30 items in the past 4 weeks vs 4 for PETV).
- DXCM has more recent analyst coverage (25 ratings vs 1 for PETV).
- Company
- DexCom Inc.
- PetVivo Holdings Inc.
- Price
- $72.74-0.92%
- $1.02-4.67%
- Market cap
- $28.08B
- $12.4M
- 1M return
- +21.17%
- -
- 1Y return
- -16.20%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 30
- 4
- Recent ratings
- 25
- 1
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
PetVivo Holdings Inc.
PetVivo Holdings, Inc., a veterinary biotech and biomedical device company, engages in the licensing and commercializing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Kush, a veterinarian-administered joint injection for the treatment of osteoarthritis and lameness in dogs and horses. The company's pipeline products include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. is headquartered in Minneapolis, Minnesota.
Latest DXCM
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)
- Director Driscoll Rimma was granted 5,605 shares, increasing direct ownership by 48% to 17,319 units (SEC Form 4)
- Director Ashley Euan A. was granted 5,565 shares, increasing direct ownership by 78% to 12,731 units (SEC Form 4)
- Director Collins Richard Alexander was granted 5,605 shares (SEC Form 4)
Latest PETV
- Large owner A.L. Sarroff Fund, Llc gifted 200,000 shares (SEC Form 4)
- Large owner A.L. Sarroff Fund, Llc bought $100,000 worth of shares (250,000 units at $0.40) (SEC Form 4)
- Chief Financial Officer Lowenthal Garry N was granted 66,421 shares (SEC Form 4)
- Chief Executive Officer Lai John was granted 66,421 shares (SEC Form 4)
- PTOP's AI Partner Tier 1 AI, Signs Contract With OTCQX:PETV as Enterprise Client
- SEC Form 4 filed by Rudelius Robert James
- PetVivo Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities
- SEC Form 4 filed by A.L. Sarroff Fund, Llc
- SEC Form 4 filed by Rudelius Robert James
- SEC Form 4 filed by Ruben Joshua David